Vaccines for close contacts of Bundibugyo virus patients
Part of Infections clinical trials.
This study tests vaccines that may protect people who have been exposed to Bundibugyo virus, a rare but serious disease. If you qualify, you would receive a vaccine and be monitored to see how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been in close contact with someone who was recently diagnosed with Bundibugyo virus disease within the last 21 days.
- You must be at least 1 year old.
- You or your parent/guardian must agree to the study and sign a consent form.
- You must be willing to provide identification, such as a participant card or iris scan, and be reachable by phone or address.
- You must not have had a confirmed Bundibugyo virus infection in the past.
- You must not have been vaccinated against Bundibugyo virus before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new Ebola vaccine to see if it is safe and how well it works. Healthy volunteers receive the vaccine and are monitored for side effects and immune response.
This trial tests a new medicine to prevent Ebola after you have been exposed. If you had close contact with someone who has Ebola in the last 5 days, this study could help you stay healthy.
This study tests a new experimental vaccine designed to protect against Sudan virus, a rare but serious disease. Researchers will check if the vaccine is safe and helps your immune system fight off the virus.
This study tests if a booster dose of one of two Ebola vaccines (Ervebo® or Zabdeno®) is safe and works well in people who already got an Ebola vaccine more than 4 months ago. It's especially for people living in the Democratic Republic of Congo (DRC) who may have been vaccinated before and might need a stronger, longer-lasting immune response.
This trial provides an experimental antibody treatment called ansuvimab to people who have Ebola or have been recently exposed to it. The goal is to help their bodies fight the virus and prevent illness.
This trial tests two doses of a dengue vaccine in healthy infants and toddlers aged 6 to 21 months. It aims to see if the vaccine is safe and helps protect against dengue fever.
Hear when a new Ebola Hemorrhagic Fever trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.